Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is an interventional study, to assess feasibility and safety of durvalumab (MEDI4736) in
neo-adjuvant setting in patients with resectable NSCLC. Additional analyses of potential
imaging biomarkers, e.g. Zr-89 labelled durvalumab (MEDI4736), ex vivo In-111-oxine labelled
CD8+ T-cells and high-resolution immune cell imaging, in relation to immunotherapy induced
immune responses on quantitative immune histochemical analysis of the resected tumor
specimen, will be performed.